April 22, 2025
CaaMTech Spins Out Transneural Therapeutics to Develop Novel Neuroplastogens
Industry veteran Charmaine Lykins to helm Transneural as it transforms the treatment of neuropsychiatric disorders
Press
November 14, 2024
FDA Blesses CaaMTech’s Psychedelic Functional Unblinding Strategy
CaaMTech’s new clinical trial design solves the emergent functional unblinding problems plaguing psychedelic medicine developers
March 27, 2024
Dr. Nathan Sackett Joins CaaMTech to Advise on Neuropsychiatry
Dr. Sackett also serves as the Director of the University of Washington Center for Novel Therapeutics in Addiction Psychiatry
November 16, 2021
CaaMTech Teams Up with University of Wyoming to Study Psychedelics as Treatments for Addiction
Scientists will assess the potential of psychedelic compounds for treating addiction
September 8, 2021
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing …
February 10, 2021
Patent Combining Psychedelics with Cannabinoids Allowed by USPTO
CaaMTech’s first of over one hundred patent applications is nearing the finish line
December 9, 2020
CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth
The Manke Lab at UMass Dartmouth is a global leader in novel tryptamine synthesis and characterization
December 1, 2020
CaaMTech Collaborates with The Leibniz Institute for Natural Product Research to Investigate Psychedelic Mushrooms
The collaborative research aims to fill several gaps in the scientific understanding of the chemical composition of psychedelic psilocybin-containing mushrooms
July 6, 2020
CaaMTech Synthesizes Novel Tryptamine Prophoria™, Amphoria™
CaaMTech scientists hope to unlock the euphoria experienced from the consumption of psilocybin mushrooms
May 7, 2020
CaaMTech Collaborates with National Institutes of Health to Research Psychedelics
The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech’s library of tryptamine-based compounds
